Gan & Lee Pharmaceuticals (603087.SH) announced that the company and its European subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, have received notification from the European Commission. The company's product, Insulin Aspart Injection (brand name: Dazparda®), has obtained marketing authorization in the European Union, Iceland, Liechtenstein, and Norway. The approval covers the treatment of diabetes in adults, adolescents, and children aged 1 year and above.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments